London (UK), Rehovot (Israel) August 10th, 2023
Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com
London UK. The extraordinary meeting of Shareholders which took place on August 8th in person and digitally with more than 90% participation voted unanimously to delegate to the Board the power of creating 1.5 million new shares in particular for including new investors and acquiring services. The next Annual Shareholder Meeting with all financial results was announced to take place in September. The Chairman, Dr. Max Herzberg, gave an overview and perspectives of the progresses made during the last few months and commented: “The loyalty and quality of the Shareholders, the Board members and of the Team is one of the very important assets of our Company. We are impressed in particular by the fact that all holders of convertible loans converted them into shares showing their confidence in Vidac Pharma future “
Rehovot (Israel), London (UK)
About Vidac Pharma: Vidac Pharma Holdings Plc. London, is the holding company of Vidac Pharma Ltd. Rehovot. The Company is a clinical stage biopharmaceutical company dedicated to discovering and developing First-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases.
Disclaimer
The following information does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only.
Vidac Pharma Holding PLC
Dr. Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
http://www.vidacpharma.com/
investors@vidacpharma.com
+972-54-4257381
+972 (0)779300647